SCHEMBL2875901

SCHEMBL2875901

CC1CN(C(=O)OCc2ccccc2)CCN(C(=O)OC(C)(C)C)C1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.57
PDK1 Q15118 1/20 0.54
PDK2 Q15119 1/20 0.54
PDK3 Q15120 1/20 0.54
PDK4 Q16654 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
HTT P42858 1/20 0.47
CYP2C19 P33261 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
HTR2C P28335 1/20 0.44
OPRK1 P41145 1/20 0.43
NR1H2 P55055 2/20 0.43
NR1H3 Q13133 2/20 0.43
MMP1 P03956 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27019090 1.00 PARP1 (0.57) PARP1PDK1PDK2PDK3PDK4
SCHEMBL27011301 0.91 PARP1 (0.55) PARP1PDK1PDK2PDK3PDK4
SCHEMBL24325790 0.91 PARP1 (0.55) PARP1PDK1PDK2PDK3PDK4
SCHEMBL2380922 0.90 PDK1 (0.67) PARP1PDK1PDK2PDK3PDK4
SCHEMBL8117814 0.90 PDK1 (0.67) PARP1PDK1PDK2PDK3PDK4
SCHEMBL30289307 0.88 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL1375861 0.87 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL957813 0.87 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL3766378 0.87 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL30289174 0.86 PARP1 (0.57) PARP1PDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362009-B2 Substituted diazepan orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-01-29 US disclosed
EP-2214676-B1 SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-11-21 EP disclosed
US-20100256121-A1 SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-10-07 US disclosed
EP-2214676-A1 SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2010-08-11 EP disclosed
WO-2009058238-A1 SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256121-A1 SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR PARP1 4495/4885PDK1 2643/4885PDK2 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.